Bonkers Bargain: contract delays
This medical imaging advanced analytics company delivering insights in neuroscience, had been growing fast over recent years and, following recent share price falls, looks cracking value. Our in-depth commentary here highlights its appeal in a sector which is predicted to grow significantly over the coming years. The order book offers plenty of visibility and this fascinating business is certainly worth a close look. Encouraging results from a drug being developed for Alzheimers disease is positive, although news of contract delays has pushed the shares lower.
IXICO (LON:IXI) is an Artificial Intelligence (‘AI’) data analytics company delivering intelligent insights in neuroscience. Its purpose is to advance medicine and human health in neuroscience by converting raw clinical trial data into clinically meaningful information. Through the deployment of novel Artificial Intelligence (‘AI’) algorithms, IXICO analyses and interprets brain scans and wearable biosensor data to enable better trial design, patient selection and ultimately better clinical outcomes across all phases of clinical evaluation. The Group is a trusted partner to the global pharmaceutical industry, developing new therapies for neurological conditions with unmet clinical needs, including Alzheimer’s, Parkinson’s and Huntington’s diseases.Background…